Open AccessFocus on the role of mitochondria in NLRP3 inflammasome activation: A prospective target for the treatment of ischemic stroke (Review)
Author(s) -
Xiaolu Zhang,
Wenyun Zeng,
Yue Zhang,
Qun Yu,
Miao Zeng,
Jiali Gan,
Wenlan Zhang,
Xijuan Jiang,
Huhu Li
Publication year - 2022
Publication title -
international journal of molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.048
H-Index - 90
eISSN - 1791-244X
pISSN - 1107-3756
DOI - 10.3892/ijmm.2022.5130
Subject(s) - inflammasome , neuroinflammation , pyrin domain , mitochondrion , medicine , stroke (engine) , hypoxia (environmental) , neuroscience , ischemia , neuroprotection , inflammation , immunology , bioinformatics , pharmacology , biology , microbiology and biotechnology , chemistry , mechanical engineering , organic chemistry , oxygen , engineering
Post‑ischemic neuroinflammation induced by the innate local immune response is a major pathophysiological feature of cerebral ischemic stroke, which remains the leading cause of mortality and disability worldwide. NLR family pyrin domain containing (NLRP)3 inflammasome crucially mediates post‑ischemic inflammatory responses via its priming, activation and interleukin‑1β release during hypoxic‑ischemic brain damage. Mitochondrial dysfunctions are among the main hallmarks of several brain diseases, including ischemic stroke. In the present review, focus was addressed on the role of mitochondria in cerebral ischemic stroke while keeping NLRP3 inflammasome as a link. Under ischemia and hypoxia, mitochondria are capable of controlling NLRP3 inflammasome‑mediated neuroinflammation through mitochondrial released contents, mitochondrial localization and mitochondrial related proteins. Thus, inflammasome and mitochondria may be attractive targets to treat ischemic stroke as well as the several drugs that target the process of mitochondrial function to treat cerebral ischemic stroke. At present, certain drugs have already been studied in clinical trials.